Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases

Author(s): Tamer E. Fandy

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 17 , 2009

Become EABM
Become Reviewer
Call for Editor


Although chemotherapy is considered the mainstay of cancer therapy, unfortunate side effects of chemotherapy create a continuous demand for developing other novel and specific targets for cancer therapy. Re-expression of epigenetically silenced tumor suppressor genes is a rational strategy for the treatment of human neoplasms. Epigenetic modifiers like DNA methyltransferase (DNMT) inhibitors and histone deacteylase (HDAC) inhibitors induce the re-expression of epigenetically silenced genes in vitro and in vivo. Moreover, they demonstrate safety and efficacy against neoplastic diseases in clinical trials. DNMT inhibitors like 5-azacytidine and 5-aza-2-deoxycytidine are currently FDA approved for the treatment of myelodysplastic syndrome. Nonetheless, the mechanism of action behind their clinical efficacy remains unclear. Ongoing clinical trials are attempting to identify tumor suppressor genes that upon re-expression can induce remission and cure in patients. On the other hand, the pleiotropic biological effects of DNMT inhibitors and recent reports demonstrating lack of association between clinical response and methylation reversal of candidate tumor suppressor genes, suggest a complex mechanism behind their clinical efficacy that may involve a cytotoxic effect.

Keywords: 5-azacytidine, decitabine, zebularine, RG108, DNA methylation, DNA methyltransferases

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [2075 - 2085]
Pages: 11
DOI: 10.2174/092986709788612738
Price: $65

Article Metrics

PDF: 14